These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 10410229)
21. Quinolones for treatment of nosocomial pneumonia: a meta-analysis. Shorr AF; Susla GB; Kollef MH Clin Infect Dis; 2005 Feb; 40 Suppl 2():S115-22. PubMed ID: 15712099 [TBL] [Abstract][Full Text] [Related]
22. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)]. Kohno S; Watanabe A; Mikasa K; Asano K Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412 [No Abstract] [Full Text] [Related]
23. Antimicrobial symposium. Part IV. Cephalosporins. Cooper TW; Gibbs WJ; Bronze MS; Greenfield RA J Okla State Med Assoc; 2006 Dec; 99(12):579-83. PubMed ID: 17310925 [No Abstract] [Full Text] [Related]
24. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085 [TBL] [Abstract][Full Text] [Related]
25. [Antibiotic therapy of bronchial infections. 2: Community acquired and nosocomial pneumonias]. Buchenroth M MMW Fortschr Med; 1999 Dec; 141(49-50):48-50. PubMed ID: 10726149 [No Abstract] [Full Text] [Related]
26. Quinolones in 2005: an update. Van Bambeke F; Michot JM; Van Eldere J; Tulkens PM Clin Microbiol Infect; 2005 Apr; 11(4):256-80. PubMed ID: 15760423 [TBL] [Abstract][Full Text] [Related]
27. Pharmaceutical industry research and cost savings in community-acquired pneumonia. Kessler LA; Waterer GW; Barca R; Wunderink RG Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020 [TBL] [Abstract][Full Text] [Related]
28. [A. Classification of antibiotics. 4/12--The quinolones]. Medjoub M; Mandy B; Woronoff-Lemsi MC Soins; 2002 Oct; (669):51-2. PubMed ID: 12432686 [No Abstract] [Full Text] [Related]
32. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines]. Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455 [TBL] [Abstract][Full Text] [Related]
33. Pharmacology of the fluoroquinolones. Scully BE Urology; 1990 Jan; 35(1 Suppl):8-10. PubMed ID: 2404373 [No Abstract] [Full Text] [Related]
34. In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone. Jones RN J Chemother; 1989 Jul; 1(4 Suppl):165-7. PubMed ID: 16312353 [No Abstract] [Full Text] [Related]
36. [Should fluoroquinolones be restricted in hospitals?]. Shah PM Enferm Infecc Microbiol Clin; 1990; 8(6):336-7. PubMed ID: 2081166 [No Abstract] [Full Text] [Related]
37. Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia. Lin Y; Su W; Xu Z; Bai Y Chin Med J (Engl); 2001 Feb; 114(2):212-3. PubMed ID: 11780213 [No Abstract] [Full Text] [Related]
38. Prulifloxacin: a new antibacterial fluoroquinolone. Prats G; Rossi V; Salvatori E; Mirelis B Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207 [TBL] [Abstract][Full Text] [Related]
40. [The role of "respiratory" fluoroquinolones in current antibacterial treatment of extrahospital pneumonia]. Sinopal'nikov AI Ter Arkh; 2002; 74(4):80-5. PubMed ID: 12043253 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]